Axsome Therapeutics (AXSM) Announces FDA Approval of AUVELITY
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Axsome Therapeutics (AXSM) Rallies After Auvelity Gains FDA Approval
August 19, 2022 2:13 PM EDTBiopharmaceutical company Axsome Therapeutics (NASDAQ: AXSM) surged Friday after it announced that the U.S. Food and Drug Administration (FDA) has approved Auvelity for treating major depressive disorder (MDD) in adults.
Axsome shares hit a high of $61.11 following the news. They have since... More
Cowen Reiterates Outperform, $130 PT on Axsome Therapeutics (AXSM) Following FDA Approval
August 19, 2022 10:39 AM EDTCowen analyst Joseph Thome reiterated an Outperform rating and $130.00 price target on Axsome Therapeutics (NASDAQ: AXSM) following news that AXS-05 (Auvelity) has been approved for the treatment of MDD nearly one year after the therapy's initial PDUFA date.
The analyst... More
Axsome Therapeutics (AXSM) Climbs 40% Following FDA Approval of AUVELITY
August 19, 2022 7:23 AM EDTAxsome Therapeutics (NASDAQ: AXSM) Climbs 40% Following FDA Approval of AUVELITY
... More